Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1 Hematologic Neoplasms 1

Interventions

Specimen Handling 150 pembrolizumab 132 Magnetic Resonance Spectroscopy 120 Cyclophosphamide 118 Biopsy 106 fludarabine 90 Nivolumab 61 Carboplatin 55 Radiotherapy 49 Cisplatin 49 Gemcitabine 48 venetoclax 43 Paclitaxel 43 Cetuximab 40 fludarabine phosphate 39 Ipilimumab 36 Fluorouracil 35 atezolizumab 34 Bevacizumab 33 durvalumab 30 Radiation 30 Oxaliplatin 29 X-Rays 28 Leucovorin 28 Dexamethasone 28 Azacitidine 27 Irinotecan 26 Cytarabine 26 Radiosurgery 24 Injections 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Homoharringtonine × 90 days × Clear all

NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡